GlassScriptPhysician profile
Chad L Bryan
NPI 1467442814
$25,411.69
in general payments reported to CMS, 2019-2025
46 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12K · 2022: $4,868 · 2023: $4,769 · 2024: $2,031 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,526 · Travel and Lodging: $1,625 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,526.01 |
| Travel and Lodging | $1,625.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $15,250.28 | 2021-2024 | Axonics, Bulkamid |
| Abbvie INC. | $2,031.90 | 2021-2025 | |
| Endo Pharmaceuticals INC. | $1,778.87 | 2021-2024 | Xiaflex, Aveed, Edex |
| Pfizer INC. | $963.53 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $644.91 | 2023-2025 | Orgovyx, Gemtesa |
| Janssen Biotech, INC. | $548.55 | 2023-2025 | Erleada, Carvykti, Rybrevant |
| Dendreon Pharmaceuticals LLC | $516.77 | 2021-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $419.40 | 2021-2025 | |
| Astellas Pharma US INC | $300.84 | 2021-2025 | Xtandi, Myrbetriq |
| Merck Sharp & Dohme LLC | $262.69 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Novartis Pharmaceuticals Corporation | $240.93 | 2022-2025 | |
| Progenics Pharmaceuticals, INC. | $197.89 | 2022-2025 | Pylarify |
| Astrazeneca Pharmaceuticals LP | $165.10 | 2022-2025 | Lynparza, Bevespi Aerosphere |
| Myriad Genetic Laboratories, INC. | $143.24 | 2022-2024 | Prolaris |
| Myovant Sciences INC. | $128.85 | 2021-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $126.05 | 2024-2025 | Urolift, Barrigel |
| Coloplast Corp | $118.46 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $115.53 | 2023-2024 | Yonsa |
| Boston Scientific Corporation | $110.15 | 2021-2025 | Axonics, Spaceoar Vue System - 10ml |
| Urovant Sciences INC | $104.67 | 2022 | |
| Seagen INC. | $99.99 | 2025 | |
| Tolmar, INC. | $96.63 | 2023-2025 | Eligard |
| Tolmar Pharmaceuticals, INC. | $93.66 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $91.90 | 2022-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Amgen INC. | $87.60 | 2021-2022 | |
| Acerus Pharmaceuticals Corporation | $69.84 | 2021-2022 | |
| Telix Pharmaceuticals | $63.64 | 2023-2025 | Illuccix |
| Procept Biorobotics Corporation | $62.86 | 2023-2024 | Aquabeam System, Aquabeam Robotic System |
| Antares Pharma, INC. | $58.28 | 2022-2025 | Xyosted |
| Blue Earth Diagnostics | $58.04 | 2021-2024 | |
| Accord Healthcare, INC. | $51.81 | 2025 | |
| Urogen Pharma, INC. | $45.84 | 2022-2023 | Jelmyto |
| Endo USA, INC. | $43.96 | 2024-2025 | Xiaflex, Aveed |
| Halozyme INC | $41.91 | 2023 | |
| Immunitybio, INC. | $40.09 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $39.02 | 2025 | Azmiro |
| Bluewind Medical | $36.06 | 2024 | Revi |
| 180 Medical, INC. | $27.75 | 2021 | |
| Clarus Therapeutics INC. | $25.74 | 2021 | |
| Medtronic, INC. | $20.03 | 2022 | |
| Allergan, INC. | $16.00 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.92 | 2025 | Adstiladrin |
| Olympus America INC. | $15.77 | 2023 | Itind System |
| Travere Therapeutics, INC. | $14.46 | 2021 | |
| Shionogi INC | $14.30 | 2021 | |
| Angiodynamics, INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.